Biotechnology Market Research Articles

The impact of firm strategies on stock market value in the biotechnology industry

To what degree do stock holders extend or withhold external finance to or from publicly traded biotech firms and why? To address this question, two firms are considered here; the results suggest that the most significant events favourably altering investor valuation of firms in the diagnostic segment of the biotechnology market are those which are distributional and knowledge-gathering in nature. Buyouts of firms in the therapeutic segment of the biotechnology market play a large role in the extraction of external finance, particularly because the purchasing of another firms’ previous labours can significantly lower the costs of bringing new products to market.

Transcriptome analysis reveals absence of unintended effects in drought-tolerant transgenic plants overexpressing the transcription factor ABF3

BackgroundPlants engineered for abiotic stress tolerance may soon be commercialized. The engineering of these plants typically involves the manipulation of complex multigene networks and may therefore have a greater potential to introduce pleiotropic effects than the simple monogenic traits that currently dominate the plant biotechnology market. While research on unintended effects in transgenic plant systems has been instrumental in demonstrating the substantial equivalence of many transgenic plant systems, it is essential that such analyses be extended to transgenic plants engineered for stress tolerance. Drought-tolerant Arabidopsis thaliana were engineered through overexpression of the transcription factor ABF3 in order to investigate unintended pleiotropic effects. In order to eliminate position effects, the Cre/lox recombination system was used to create control plant lines that contain identical T-DNA insertion sites but with the ABF3 transgene excised. This additionally allowed us to determine if Cre recombinase can cause unintended effects that impact the transcriptome.ResultsMicroarray analysis of control plant lines that underwent Cre-mediated excision of the ABF3 transgene revealed only two genes that were differentially expressed in more than one plant line, suggesting that the impact of Cre recombinase on the transcriptome was minimal. In the absence of drought stress, overexpression of ABF3 had no effect on the transcriptome, but following drought stress, differences were observed in the gene expression patterns of plants overexpressing ABF3 relative to control plants. Examination of the functional distribution of the differentially expressed genes revealed strong similarity indicating that unintended pathways were not activated.ConclusionsThe action of ABF3 is tightly controlled in Arabidopsis. In the absence of drought stress, ectopic activation of drought response pathways does not occur. In response to drought stress, overexpression of ABF3 results in a reprogramming of the drought response, which is characterized by changes in the timing or strength of expression of some drought response genes, without activating any unexpected gene networks. These results illustrate that important gene networks are highly regulated in Arabidopsis and that engineering stress tolerance may not necessarily cause extensive changes to the transcriptome.

Experimental Techniques to Evaluate <i>In Vitro</i> Trabecular Bone Properties and Emerging Numerical Model

Economical reasons to research and develop new materials are very strong and the main market for biotechnology is human health. Bone is one of the most studied biological material; data and models at different organization levels describe relevant features needed in different applications. Depending on the type of bone, the anatomical location, the human population considered and the level taken into account, the descriptions can differ substantially. In this work, we present a set of properties (mechanical and architectural ones) measured on fresh trabecular bones samples that were extracted from femur heads of live donors with hip total replacement. Standard procedures to preserve the samples were followed. Engineering and clinical tests were performed and custom-built tools were made to adapt the available equipment.

Impact Making Biotechnology Firms in India

For long time IT industry has dominated the Indian market. The Biotechnology sector in India, although nascent at present time and accounting for a mere 2% of the global Biotechnology market, is poised for an exponential growth over the next 5-10 years, with an expected global market share of 10%. Finally, India’s biotech sector is ready to storm the business world with innovative products. Powered by growing competence in producing low cost innovative as well as generic drugs and vaccines, Biotech firms from Indian origin are fast emerging as global majors, promising to create substantial opportunities for the Indian economy. The government has also come out with enabling policies, allowing these firms to exploit India’s vast pool of technical and scientific manpower to make a global impact. Today, there are around 325 companies in India, which produce specialised products and services in various sectors of biotechnology. The present research attempts to discover the factors that qualify these firms as Imapct making. This study limits case analysis of four Indian biotechnology firms namely Biocon, Nicholas Piramal India Limited, Dr Reddy's Laboratories & Panacia Biotech, which havde already created a place for temselves in the market. The study will attempt in unfolding different aspect of these firms. Few objectives are as follows: 1. Biotechnology market in India. 2. Factors (endogenous & exogenous) affecting biotech firms & market. 3. To understand the firm architecture that includes nature of business, products, markets, segments, structure, competency etc. 4. Understand the business processess 5. Sustainability & Growth strategies of these firms. 6. How & why these firms are ahead & impact making in India. The outcome of this study will be to identify the above mentioned issues that will aid other non impact making biotech firms to fulfill the gaps.

Biotechnological Manufacturing Options for Organic Chemistry

Industrial biotechnology or white biotechnology is an area of growing academic, public and private interest. The global white (or industrial) biotechnology market of ~50 billion US$ is smaller than the red biotechnology (pharmaceutical) market (>70 billion US$). However, industrial white biotechnology represents a greater long term business potential than red biotechnology. It is estimated that at least 20% of global chemicals (~2'290 billion US$ today) could be produced by biotechnological means in 2020. The bad news is that this potential is spread over diverse markets and various product/molecule classes. This variety is more difficult to handle on the one hand, but on the other it comes with longer life cycles. Currently there are a number of in vitro and in vivo methods available for the manufacture chemicals on an industrial scale by biotechnological means. These methods include reactions with enzymes in ordinary stirred tank chemical reactors, microbial fermentation, plant cell culture, manufacturing products with plants (pharming) or other meth- ods. This review summarises and discusses the advantages and limitations of the different in vivo and in vitro methods which could po- tentially be used for the biotechnological production of chemicals.

Biotechnology in Catalonia; Industry Analysis

Biotechnology is considered one of the key engines to achieving long-term sustainable growth. Catalonia is the main player in the Spanish biotechnology market, boasting 35 percent of the Spanish biotech R&D and 24 percent of its firms. In this report, we analyze the state of the Catalan biotechnology sector, focusing on its competitive advantages and disadvantages relative to other European biotech clusters. Our findings indicate that, in Catalonia, the biotechnology sector has the potential to affect sectors that represent 10 percent of the Catalan GDP and that employ 9.3 percent of the Catalan workforce. However, Catalan biotech is still quite small in relation to the top European bioclusters and it is only slowly catching up in some of its strategic components. The main advantages of the Catalan biotechnology sector are, first, its research effort, which has been improving steadily, thus allowing Catalonia to start closing the gap with Europe, especially in industrial biotechnology. Second, the attractiveness of Barcelona to draw key staff. The main challenge it faces is access to funding and the fact that the size of related industries in the area is smaller than their size in the top European biotech regions. Finally, 65 percent of Catalan biotechnology firms are devoted to the health sector, while the performance of biotech research in the industrial sector has been particularly competitive.

Biotechnology marketing: Insider and outsider views

This paper explores biotechnology marketing as defined, performed and organised in small biotechnology companies. Prior research has argued on the one hand that marketing-related deficiencies could explain the lack of commercial success in biotechnology. On the other hand, it has been suggested that biotechnology marketing could be different from what is considered marketing in other industries. This raises the question of whether there are deficiencies in biotechnology marketing or whether the meaning of biotechnology marketing remains unexplored with the survey-based research designs used in earlier studies. This paper is based on a novel qualitative methodology combining the insider and outsider views in the study of five cases of biotechnology marketing. The findings do not suggest that there is substantial lack of marketing effort and competence in biotechnology companies. Instead, the findings provide new knowledge on the specific nature of biotechnology marketing produced by a combination of the insider and outsider views.

Filtration industry overview: World pharma and biotechnology market 2008

This article addresses the markets, technologies and processes surrounding filtration methods in these two important industries, focusing on fluid and water filtration.

Industrial biotechnology market performance in 2007 & (cautionary) outlook for 2008

Industrial BiotechnologyVol. 4, No. 3 FEATURE COMMENTARYIndustrial biotechnology market performance in 2007 & (cautionary) outlook for 2008Roger WyseRoger WyseSearch for more papers by this authorPublished Online:3 Sep 2008https://doi.org/10.1089/ind.2008.4.252AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetails Volume 4Issue 3Sep 2008 InformationCopyright 2008, Mary Ann Liebert, Inc.To cite this article:Roger Wyse.Industrial biotechnology market performance in 2007 & (cautionary) outlook for 2008.Industrial Biotechnology.Sep 2008.252-256.http://doi.org/10.1089/ind.2008.4.252Published in Volume: 4 Issue 3: September 3, 2008PDF download

Anticipating and managing the challenges of biotechnology marketing

Biotechnology companies are facing the reality that greater emphasis must be placed on delivering products to markets as companies become increasingly evaluated on their profitability. Potential risks related to markets and technologies have to be evaluated as realistically as possible to avoid mistakes. This paper discusses the features that make biotechnology marketing different from more established industries as well as the key challenges arising from those differences. This paper draws attention to issues that are distinctively important in biotechnology marketing. First, profound technological uncertainty is a key characteristic of biotechnology. Secondly, side effects emerging after the product has been in the market can cause a shutdown of an entire product line or cut down estimated market potential. Thirdly, a biotechnology product's lifecycle can also face premature death due to challenges originating from market uncertainties. A fourth issue is the threat of obsolescence that is high in a market where new innovations are introduced at a rapid rate. A fifth issue is the capability of protecting intellectual property rights. Finally, these challenges make it difficult to estimate the size of a potential market. Controlling these challenges, however, gives a solid base to make a biotechnology company a profitable business.

Anticipating and managing the challenges of biotechnology marketing

Biotechnology companies are facing the reality that greater emphasis must be placed on delivering products to markets as companies become increasingly evaluated on their profitability. Potential risks related to markets and technologies have to be evaluated as realistically as possible to avoid mistakes. This paper discusses the features that make biotechnology marketing different from more established industries as well as the key challenges arising from those differences. This paper draws attention to issues that are distinctively important in biotechnology marketing. First, profound technological uncertainty is a key characteristic of biotechnology. Secondly, side effects emerging after the product has been in the market can cause a shutdown of an entire product line or cut down estimated market potential. Thirdly, a biotechnology product's lifecycle can also face premature death due to challenges originating from market uncertainties. A fourth issue is the threat of obsolescence that is high in a market where new innovations are introduced at a rapid rate. A fifth issue is the capability of protecting intellectual property rights. Finally, these challenges make it difficult to estimate the size of a potential market. Controlling these challenges, however, gives a solid base to make a biotechnology company a profitable business.

A framework for managing knowledge in strategic alliances in the biotechnology sector

AbstractBiotechnology is a rapidly expanding field of science that has led to the formation of a large number of companies that together form a significant sector within the Australian economy. Even though there has been considerable growth in the Australian biotechnology sector as a whole, a large percentage of Australian biotechnology firms are small and medium sized enterprises (SMEs) that suffer from a lack of funding and expertise. The development and management of effective strategic alliances are critical to the success and development of biotechnology firms as they provide opportunities to share resources and expertise, access funding and develop new ideas. However, developing and managing strategic alliances is fraught with difficulties which are compounded by size and resource asymmetries and the nature of the biotechnology market. In this paper, we identify the difficulties faced by biotechnology firms and examine the importance of knowledge management related to alliance formation and development with special reference to the Australian context. We examine the knowledge and expertise that are required to be effective in developing strategic alliances in the biotechnology sector and provide a framework for managing knowledge related to strategic alliances. We suggest that critical systems approaches, in particular creative holism, are needed to manage the various forms of knowledge associated with strategic alliances. Copyright © 2008 John Wiley & Sons, Ltd.

Indian Biotech Bazaar: A swot analysis

Biotechnology is a life science-based technique especially used in agriculture, medicine and food sciences. It is generally defined as the manipulation in organisms to generate products for the welfare of the world. Biotechnology combines disciplines such as genetics, biochemistry, microbiology, and cell biology along with information technology, chemical engineering, robotics etc. It includes basic industries such as food processing, tissue culture, plant development and other sophisticated ones such as recombinant therapeutics and diagnostics. Biotechnology, globally recognized as a rapidly emerging and far-reaching technology, is aptly described as the "technology of hope" for its promise of food, health and environmental sustainability. In India, biotechnology employs more than 10 000 people and generates roughly US$ 500 million in revenue annually. The biotechnology market has increased its sales from Rs. 50 billion in 1997 to Rs.70 billion in 2000, and is expected to cross Rs. 240 billion by the year 2010. In India, the human health biotech products account for 60% of the total market; agribiotech and veterinary 25%, medical devices, contract research and development (R&D), reagents and supplies constitute the remaining 15% Moreover, to facilitate foreign investment, capital and government policies are being revised. Other important industries include industrial enzyme manufacture, bioinformatics, and medical devices. Biotechnology has had limited appeal so far on our capital markets, and we have less then a dozen biotech companies listed on the public markets.

OVERCOMING CHALLENGES TO DELIVER TRANSGENIC HORTICULTURAL PRODUCTS TO U.S. AND OVERSEAS MARKETS

Transgenic technologies offer many scientific advantages in breeding for improved horticultural crop quality and performance. These proceedings describe multiple transgenic approaches to solving important agricultural constraints in horticultural crop production. However, very few genetically engineered horticultural crops have been released to farmers, either in the United States or overseas. This paper outlines some of the challenges in pursuing development of a transgenic crop beyond the laboratory research phase. Three examples of public sector biotechnology research, product development and market access are presented: disease resistant papaya (USA/Japan), plums (USA/Europe) and cassava (USA/Africa). The experience of researchers and policymakers involved in these projects can guide future development of other transgenic horticultural varieties.

Increased uptake of biologics in historically small molecule blockbuster-dominated therapeutic areas

The two leading therapeutic areas for biologic products, in terms of current sales and pipeline focus, are oncology and AIID (arthritis, immune and inflammatory disorders). Datamonitor has recently analysed these markets.1, 2 Biologics designed to treat cancer indications have underpinned the development of the biotechnology market since its inception in the 1980s, while AIID biologics are currently driving biotechnology market growth, due to the high demand for biologics to treat diseases such as rheumatoid arthritis and psoriasis.In this paper, we have looked outside these markets to identify whether biologic drugs are having an impact in other therapeutic markets. Many of these therapeutic markets (eg cardiovascular, central nervous system, respiratory, gastrointestinal) are dominated by small molecule blockbusters prescribed by primary care physicians. Here, we examine the cardiovascular therapeutic franchise as a case study for a market that has relied heavily on small molecule blockbusters to drive growth, and in which there is relatively low exposure to biologics.Marketed and pipeline cardiovascular biologics can largely be split into two categories: (i) early-evolution versions of drugs from mature biologic sectors (eg first-generation recombinant proteins and chimeric monoclonal antibodies), which are in the mature low-growth stages of their sales growth trajectories; and (ii) early-stage therapies based on innovative biologic technology platforms (eg gene therapies and oligonucleotides), which have the potential to help power cardiovascular franchise growth in the future. With the identification of more protein targets that play a role in specific disease aetiology, targeted therapies are set to power overall market growth. While companies operating in the oncology and AIID franchises are best equipped to use a targeted therapy strategy, franchises such as cardiovascular are beginning to awaken to the potential of a targeted therapy approach.

Cancer remains the dominant disease target for biotech through to 2010

The two leading therapeutic areas for biological products, in terms of current sales and pipeline focus, are oncology and AIID (arthritis, immune and inflammatory disorders). Datamonitor’s biotechnology strategic market analysis team recently analysed the AIID market, since this sector is currently powering biotechnology market growth, owing to high demand for biologicals to treat rheumatoid arthritis and psoriasis (Belsey, M. and Churchill, C. (2006) ‘Autoimmune and inflammatory disorder biologicals will power biotech market growth through to 2010’, J. Comm. Biotechnol., Vol. 12, No. 2, pp. 237‐241). In the current paper, we have analysed the oncology market, since biologicals designed to treat cancer indications have underpinned the development of the biotechnology market since its inception in the 1980s. Biological products treat a wide variety of cancers, of which the most prevalent are the ‘big four’ tumour types ‐ breast cancer, lung cancer, prostate cancer and colorectal cancer. In terms of technology focus, both monoclonal antibody therapeutics and recombinant proteins are set to drive cancer biological market growth. Key growth drivers include mainly Genentech and Roche products, such as Avastin (bevacizumab), Rituxan (rituximab) and Herceptin (trastuzumab), as well as Amgen products, including the second-generation recombinant proteins Neulasta (pegfilgrastim) and Aranesp (darbepoetin alfa). Across the major pharmaceutical markets, oncology biologicals generated US$10.7bn in 2004 (based on company-reported data), which Datamonitor forecasts to rise to US$29.0bn by 2010.

Autoimmune and inflammatory disorder biologicals will power biotech market growth through to 2010

Biologicals designed to treat arthritis, immune and inflammatory disorders (AIID) are currently powering biotechnology market growth. Datamonitor's biotechnology strategic market analysis team has therefore analysed this market to identify key biological products, together with growth drivers and resistors shaping the growth of this market. The AIID market covers a wide range of indications; however, the most prevalent are rheumatoid arthritis and psoriasis, which together represent a significant healthcare burden. A range of monoclonal antibody therapeutics such as Abbott/CAT's Humira are set to drive AIID biological market growth, together with Amgen/Wyeth's fusion protein Enbrel. Owing to very strong sales of Enbrel as a result of continued label expansion, Amgen is set to record the greatest biological AIID sales from 2004 to 2010. Many of the highly efficacious AIID biologicals such as Enbrel target TNF, which is rapidly emerging as the leading cytokine target for many AIID indications. Overall, AIID biologicals generated US$5.4bn in 2004, and this is set to rise to US$14.3bn by 2010: a strong compound annual growth rate of 17.9 per cent.

Autoimmune and inflammatory disorder biologicals will power biotech market growth through to 2010

Biologicals designed to treat arthritis, immune and inflammatory disorders (AIID) are currently powering biotechnology market growth. Datamonitor's biotechnology strategic market analysis team has therefore analysed this market to identify key biological products, together with growth drivers and resistors shaping the growth of this market. The AIID market covers a wide range of indications; however, the most prevalent are rheumatoid arthritis and psoriasis, which together represent a significant healthcare burden. A range of monoclonal antibody therapeutics such as Abbott/CAT's Humira are set to drive AIID biological market growth, together with Amgen/Wyeth's fusion protein Enbrel. Owing to very strong sales of Enbrel as a result of continued label expansion, Amgen is set to record the greatest biological AIID sales from 2004 to 2010. Many of the highly efficacious AIID biologicals such as Enbrel target TNF, which is rapidly emerging as the leading cytokine target for many AIID indications. Overall, AIID biologicals generated US$5.4bn in 2004, and this is set to rise to US$14.3bn by 2010: a strong compound annual growth rate of 17.9 per cent.

The Nexus between Knowledge Management in the Biotechnology Industry and Marketing

The Nexus between Knowledge Management in the Biotechnology Industry and Marketing

Microorganism Screening for Limonene Bioconversion and Correlation With RAPD Markers

The use of microorganisms for biotransformations of monoterpenes has stimulated the biotechnological market. Aiming at the highest efficiency in the process of strains screening, the application of molecular biology techniques have been proposed. Based on these aspects, the objective of this work was to select different strains able to convert limonene using fermentative process and random amplified polymorphic DNA (RAPD) markers. The results obtained in the fermentative screening, from 17 strains tested, pointed out that four microorganisms were able to convert limonene into oxygenated derivatives. The RAPD study showed a polymorphism of 96.02% and a similarity from 16.02 to 51.51%. Based on this it was possible to observe a high genetic diversity, even among strains of same species, concluding that the RAPD was not able to correlate the genetic characteristics of the microorganism with the results obtained from the biotransformation process.